New aspects in the treatment of hypertension

• Autorzy: Maretskyi V.
• Języki publikacji: EN

Abstrakty

EN

Hypertension is currently the leading cause of cardiovascular complications (heart attack, stroke) and the resulting deaths of patients. Reduced morbidity and mortality from cardiovascular complications is the main goal of treating patients suffering from high blood pressure (BP). To achieve target BP levels in the arsenal of physicians are five major classes of antihypertensive drugs: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β-blockers, diuretics. The choice of antihypertensive drug in concrete clinical situation often complicated and determined by complex factors. Among these presence of risk factors; target organ damage; associated clinical conditions, metabolic syndrome, diabetes, comorbidities; possible individual patient response to antihypertensive drugs of different classes in history; the likelihood of drug interactions; socio-economic factors, including the cost of treatment of hypertension. Promising is the use of angiotensin II receptor blockers - drugs with pleiotropic pharmacological properties that have a multicomponent antihypertensive efficacy, good tolerability, diverse organoprotection that are safe, able to enhance remote prognosis for patients with hypertension. Azilsartan medoxomil is a competitive reversible angiotensin II type 1 receptor antagonist. Azilsartan developing hypotensive effect faster, prolonged and pronounced compared to other sartans (valsartan, candesartan and olmesartan). In addition to antihypertensive action azilsartan medoxomil shows a number of additional pleiotropic effects. These include antithrombotic, antiproliferative and antyfibrotic action. It demonstrates the improvement in glucose tolerance and tissue insulin sensitivity, improves endothelial function, reduces the progression of albuminuria, proteinuria.

Słowa kluczowe

EN

new aspect; treatment; hypertension; human disease; angiotensin II receptor; risk factor; Azilsartan medoxomil drug

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2015
• Tom: 09
• Numer: 3
• Opis fizyczny: p.16-19,ref.

Twórcy

autor

Maretskyi V.

• Department of Pharmacology and Clinical Pharmacology, I.Ya.Horbachevsky Ternopil State Medical University, m.Voli, 1, Ternopil, Ukraine

Bibliografia

• 1. Ambrosova T., Kovalyova O., Ashcheulova T. (2010), The therapeutic potential of angiotensin II receptor antagonists in hypertensive patients with metabolic disorders: effect on carbohydrate and lipid profiles, Ukrainian Journal of Therapeutics. 4, 76-81.
• 2. Azilsartan medoxomil (Edarbi) the eighth ARB (2011), Med. Lett. Drugs Ther. 53 (1364), 39-40.
• 3. Baker W., White W. (2011), Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. The Annals of Pharmacotherapy, 45, 1506-1515.
• 4. Bakris G., Sica D., Weber M., White W.B., Roberts A., Perez A., Cao C., Kupfer S. (2011), The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens., 13 (2), 81-88.
• 5. Chazova I., Martynyuk T., Ratova L. (2011), The focus of attention - angiotensin converting enzyme inhibitors: ramipril in hypertension. Systemic Hypertensions, 8 (3), 5-10.
• 6. Dyadyk A., Bahriy A., Chomenko M. et al. (2014), Hypertension in 2014: classification, diagnosis, treatment. News of Medicine and Pharmacy, 482, 53-69.
• 7. Kajiya T., Ho C., Wang J., Vilardi R., Kurtz T.W. (2011), Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J. Hypertens, 29 (12), 2476-2483.
• 8. Kirichenko A. (2012), Indications for use of AT1-receptor blockers in patients with hypertension. Handbook of Outpatient Physician, 10, 6-8.
• 9. Korost Y., Bula L., Suprunyuk V. (2014), The application features angiotensin II receptor blockers in the treatment of cardiovascular diseas. Medicines of Ukraine, 1 (177), 19-23.
• 10. Mancia G., Fagard R., Narkiewicz K. et al. (2013), 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 34, 2159–2219.
• 11. New therapeutic possibilities of control of hypertension: a modern angiotensin receptor antagonist – Edarbi (azilsartan medoxomil) (2014), Consilium Medicum, 10, 30-31.
• 12. Ostroumova O., Smolyarchuk E., Khvorostyanaya I. (2010), New approaches to the treatment of hypertension: the choice of the optimal drug to the choice of the optimal combination. Rational Pharmacotherapy in Cardiology, 6 (5), 709-716.
• 13. Rakugi H., Enya K., Sugiura K., Ikeda Y. (2012), Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens. Res., 35, 552–558.
• 14. Savustyanenko A. (2014), New perspectives in achieving blood pressure control: focus on new sartan - azilsartan medoxomil. Hypertension, 4 (36), 23-27.
• 15. Shilov A. (2014), Sartans in the practice of primary health care in the treatment of hypertension. Farmateka, 9 (282), 39-44.
• 16. Sica D., White W., Weber M., Bakris G.L., Perez A., Cao C., Handley A., Kupfer S. (2011), Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J. Clin. Hypertens, 13(7), 467-472.
• 17. Sirenko Y. (2012), Angiotensin II receptor blockers in the treatment of hypertension: myths and reality. Hypertension, 4 (24), http://www.mif-ua.com/archive/article/33325 (accessed: 2013.03.05).
• 18. Svischenko E., Bezrodna L. (2012), Angiotensin II receptor blockers in the treatment of hypertension, Publisher O. Zaslavsky.
• 19. Tseluyko V., Ocheretyana N. (2014), The new representative of the sartans group azilsartan medoxomil (Edarbi): equal among equals or special? Health of Ukraine. Cardiology. Rheumatology. Heart Surgery, 4, 18-19.
• 20. White W., Weber M., Sica D., Bakris G.L., Perez A., Cao C., Kupfer S. (2011), Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension, 57, 413-420.
• 21. Zaharova N., Kuz’mina-Krutetskaya S. (2011), Clinical pharmacology of sartans: class-effect and pharmacodynamic characteristics of drugs. Systemic Hypertensions, 8 (3), 10-16.